靶向药物联合阿霉素靶向制剂治疗Her-2阳性乳腺癌的效果及安全性研究

摘要

Objective: To study the efficacy and safety of the targeted drug trastuzumab combined with adriamycin liposome solution for HER-2-positive breast cancer.Methods: A total of 112 patients with breast cancer who received chemotherapy in Department of Cardiothoracic Breast Surgery, Guangdong TongJiang Hospital between May 2014 and April 2016 were selected as the research subjects and divided into two groups by random number table, liposome group received trastuzumab+adriamycin liposome chemotherapy, and the control group received trastuzumab+adriamycin chemotherapy.Before chemotherapy as well as 4 weeks and 8 weeks after chemotherapy, serum levels of tumor markers, cytokines and myocardial injury indexes were detected, the electrocardiogram was conducted and the degree of myocardial injury was determined.Results: Four weeks and eight weeks after chemotherapy, serum CEA, CA15-3, TPS, CTGF, TGF-β, TSGF, VEGF and MK levels of both groups were significantly lower than those before chemotherapy, serum CK-MB and cTnI levels were significantly higher than those before chemotherapy, limb leads QRS amplitudes and chest leads QRS amplitudes were significantly lower than those before chemotherapy, serum CEA, CA15-3, TPS, CTGF, TGF-β, TSGF, VEGF, MK, CK-MB and cTnI levels of liposome group were significantly lower than those of control group, and the limb leads QRS amplitudes and chest lead QRS amplitudes were significantly higher than those of control group.Conclusions: application of targeted drug combined with adriamycin liposome solution in HER-2-positive breast cancer can improve the curative effect and reduce the cardiotoxicity.%目的:研究靶向药物曲妥珠单抗联合阿霉素脂质体方案用于HER-2阳性乳腺癌的有效性及安全性.方法:选择在本院心胸乳腺外科接受化疗的112例乳腺癌患者作为研究对象,通过随机数表法将上述患者分为两组,脂质体组按照妥珠单抗+阿霉素脂质体的方案进行化疗,对照组患者按照妥珠单抗+阿霉素的方案进行化疗.化疗前及化疗后4、8周时,测定血清中肿瘤标志物、细胞因子、心肌损伤指标的含量,进行心电图检查并测量心肌损伤程度.结果:治疗后4周、8周时,两组血清中CEA、CA15-3、TPS、CTGF、TGF-β、TSGF、VEGF、MK的含量均显著低于治疗前,血清中CK-MB、cTnI的含量显著高于治疗前,肢体导联QRS振幅、胸导联QRS振幅显著低于治疗前且脂质体组患者血清中CEA、CA15-3、TPS、CTGF、TGF-β、TSGF、VEGF、MK、CK-MB、cTnI的含量均显著低于对照组,肢体导联QRS振幅、胸导联QRS振幅显著高于对照组.结论:靶向药物联合阿霉素脂质体用于HER-2阳性乳腺癌能够改善疗效、减轻心肌毒性.